Table 2 Patient characteristics
Included patients (n=102) | |
|---|---|
Age, years* | 69 (24–91) |
Male sex, n (%) | 79 (77.5) |
APACHE II** | 12.4 ± 5.68 |
Clinical status, n (%): | |
- Severe sepsis | 48 (47.1) |
- Shock | 8 (7.8) |
Intensive Care Unit admission, n (%) | 24 (23.5) |
Type of infection, n (%) | |
- Pneumonia | 24 (23.5) |
- Acute bronchitis | 23 (22.5) |
- Urinary tract infection | 15 (14.7) |
- Skin and soft tissue infection and surgical site infection | 15 (14.7) |
- Bacteremia | 5 (4.9) |
- Others | 20 (19.6) |
Type of CMS treatment, n (%) | |
- Empirical | 3 (2.9) |
- Directed: | 99 (97.1) |
- Pseudomonas aeruginosa | 89 (89.9) |
- Acinetobacter baumannii | 9 (9.1) |
- Klebsiella pneumoniae | 1 (1) |
1CMS daily dose (millions IU)** | 5.21 ± 2.24 |
1CMS total dose, (MU)** | 100.54 ± 92.8 |
1CMS duration, days** | 19.57 ± 15.4 |
2GFR at baseline (ml/min/1.73 m2)* | 127.9 (22.3-560) |
Patients with 3CKD at baseline, n (%) | 23 (22.5) |
4Cmin (mg/mL)* | 1.06 (0.11-5.99) |
5Cmax (mg/mL)* | 1.11 (0.15-6.62) |
Patients with nephrotoxicity at day 7, n (%) | 26 (25.5) |
- R (Risk) | 16 (61.5) |
- I (Injury) | 8 (30.7) |
- F (Failure) | 2 (7.6) |
Patients with nephrotoxicity at the end of treatment, n (%) | 50 (49) |
- R (Risk) | 13 (26) |
- I (Injury) | 23(46) |
- F (Failure) | 14 (28) |
Clinical response, n (%) | 79 (77.5) |